7.28
前日終値:
$6.99
開ける:
$6.95
24時間の取引高:
1.07M
Relative Volume:
0.86
時価総額:
$395.14M
収益:
$1.02B
当期純損益:
$-757.20M
株価収益率:
-0.4932
EPS:
-14.76
ネットキャッシュフロー:
$-257.90M
1週間 パフォーマンス:
-0.68%
1か月 パフォーマンス:
+17.04%
6か月 パフォーマンス:
-26.32%
1年 パフォーマンス:
-39.43%
Emergent Biosolutions Inc Stock (EBS) Company Profile
名前
Emergent Biosolutions Inc
セクター
電話
240-631-3200
住所
300 PROFESSIONAL DR, GAITHERSBURG, MD
EBS を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
EBS
Emergent Biosolutions Inc
|
7.28 | 397.86M | 1.02B | -757.20M | -257.90M | -14.76 |
![]()
ZTS
Zoetis Inc
|
150.03 | 70.46B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.74 | 47.78B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.59 | 45.15B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.31 | 19.16B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
297.33 | 13.56B | 2.99B | 1.21B | 1.13B | 25.06 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-30 | 開始されました | H.C. Wainwright | Buy |
2024-08-22 | 開始されました | Rodman & Renshaw | Buy |
2024-03-07 | アップグレード | The Benchmark Company | Hold → Buy |
2023-11-20 | 再開されました | JP Morgan | Underweight |
2023-08-29 | ダウングレード | The Benchmark Company | Buy → Hold |
2023-04-10 | アップグレード | The Benchmark Company | Hold → Buy |
2023-03-17 | ダウングレード | JP Morgan | Neutral → Underweight |
2022-11-10 | ダウングレード | The Benchmark Company | Buy → Hold |
2022-04-29 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2022-01-20 | アップグレード | The Benchmark Company | Hold → Buy |
2021-11-08 | ダウングレード | The Benchmark Company | Buy → Hold |
2021-05-05 | ダウングレード | Argus | Buy → Hold |
2021-04-07 | 開始されました | The Benchmark Company | Buy |
2021-02-24 | アップグレード | Chardan Capital Markets | Neutral → Buy |
2021-02-19 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
2021-01-08 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2020-09-14 | 再開されました | JP Morgan | Neutral |
2020-07-31 | 繰り返されました | Chardan Capital Markets | Buy |
2019-09-12 | 開始されました | Guggenheim | Buy |
2019-09-04 | アップグレード | Wells Fargo | Market Perform → Outperform |
2018-11-02 | アップグレード | Goldman | Neutral → Buy |
2018-08-03 | 繰り返されました | Chardan Capital Markets | Buy |
2018-06-13 | 開始されました | Argus | Buy |
2018-04-25 | ダウングレード | Wells Fargo | Outperform → Market Perform |
2018-01-24 | 開始されました | Goldman | Neutral |
2018-01-16 | 繰り返されました | Chardan Capital Markets | Buy |
2016-06-28 | 繰り返されました | Singular Research | Buy |
2016-04-15 | 開始されました | Chardan Capital Markets | Buy |
2016-03-28 | 開始されました | Singular Research | Buy |
2016-02-19 | 開始されました | Wells Fargo | Outperform |
2014-05-15 | 開始されました | Summer Street Research | Buy |
2011-05-31 | 繰り返されました | WBB Securities | Strong Buy |
2011-01-10 | 繰り返されました | Wedbush | Outperform |
2010-11-05 | 繰り返されました | Wedbush | Outperform |
2010-08-18 | アップグレード | WBB Securities | Buy → Strong Buy |
2010-08-06 | 繰り返されました | Caris & Company | Buy |
すべてを表示
Emergent Biosolutions Inc (EBS) 最新ニュース
Emergent Signs $174M Manufacturing Deal For AstraZeneca’s Covid-19 Candidate - TipRanks
What makes Emergent BioSolutions Inc. stock price move sharplyPotential Rocket List - beatles.ru
Lobbying Update: $440,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed - Nasdaq
Emergent BioSolutions to Report Second Quarter 2025 Financial Re - GuruFocus
Emergent BioSolutions Inc. to Host Q2 2025 Financial Results Conference Call on August 6 - Nasdaq
Emergent BioSolutions Q2 2025 Earnings Call Scheduled for August 6: Key Details Inside - Stock Titan
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 - TradingView
Government Contract Update: $52M payment to EMERGENT BIOSOLUTIONS CANADA INC - Nasdaq
Emergent BioSolutions signs contract modification award for CNJ-016 - MSN
Benchmark Co. Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts - The Manila Times
Emergent BioSolutions Stock Rises After New US Order For Smallpox Complication Therapy - Stocktwits
Emergent BioSolutions secures contract modification for smallpox treatment By Investing.com - Investing.com South Africa
Emergent BioSolutions secures contract modification for smallpox treatment - Investing.com Australia
Emergent BioSolutions (EBS) Expands Smallpox Vaccine Contract wi - GuruFocus
Emergent BioSolutions (EBS) Secures Smallpox Preparedness Contra - GuruFocus
Emergent BioSolutions Gets $51.9 Million Contract Modification for Smallpox Preparedness - MarketScreener
Emergent BioSolutions stock rises on government contract modification By Investing.com - Investing.com Canada
Emergent BioSolutions stock rises on government contract modification - Investing.com
Emergent BioSolutions Secures Contract Modification for Additional VIGIV Doses to Support U.S. Smallpox Preparedness - Quiver Quantitative
Emergent BioSolutions Strengthens US Biodefense Arsenal with $51.9M Government Contract - Stock Titan
Emergent BioSolutions Secures $51.9 Million Contract Modificatio - GuruFocus
Lobbying Update: $40,000 of EMERGENT BIOSOLUTIONS lobbying was just disclosed - Quiver Quantitative
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way? - simplywall.st
Emergent BioSolutions adds KLOXXADO to online naloxone platform By Investing.com - Investing.com India
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® ( - GuruFocus
Investors Can Still File Late Claims in Emergent BioSolutions Settlement - TradingView
Emergent BioSolutions Inc.(NYSE: EBS) added to Russell 2500 Value Index - MarketScreener
Is Emergent BioSolutions, Inc. overvalued or undervalued? - MarketsMojo
Emergent BioSolutions secures $62.4 million contract for botulism antitoxin By Investing.com - Investing.com South Africa
Emergent BioSolutions to join Russell 3000 Index after market close June 27 - Investing.com
EBS Stock Up 1.4% after 1-Day Win Streak - Trefis
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030 - GlobeNewswire
Government Contract Update: $62M payment to EMERGENT BIOSOLUTIONS CANADA INC - Nasdaq
BRIEF—LigaChem links up with NovaRock - The Pharma Letter
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact Its Attorneys Now, Securities Fraud Case Pending, Firm Investigating CEO’s Insider Sales - ACCESS Newswire
Emergent BioSolutions at Jefferies Conference: Strategic Transformation By Investing.com - Investing.com Canada
Squarepoint Ops LLC Has $451,000 Stake in Emergent BioSolutions Inc. (NYSE:EBS) - Defense World
Emergent BioSolutions (EBS) Partners with Foundation for Opioid Awareness | EBS Stock News - GuruFocus
Emergent BioSolutions Supports Victoria's Voice Foundation's Nat - GuruFocus
Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies | EBS Stock News - GuruFocus
Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies - The Manila Times
Breaking: Dramatic 34% Drop in US Opioid Deaths as Emergent Expands Life-Saving Naloxone Access - Stock Titan
Vaccine Contract Manufacturing Market Set to Witness - openPR.com
Biodefense Market Set to Witness Significant GrowthEmergent BioSolutions Inc., SIGA Technologies - openPR.com
Bank of America Corp DE Boosts Stake in Emergent BioSolutions Inc. (NYSE:EBS) - Defense World
Northern Trust Corp Acquires 3,692 Shares of Emergent BioSolutions Inc. (NYSE:EBS) - Defense World
Emergent BioSolutions discloses CEO stock purchase - MSN
Emergent Biosolutions Settlement Receives Preliminary Approval - TipRanks
Emergent BioSolutions at RBC Conference: Strategic Turnaround Focus By Investing.com - Investing.com India
Emergent BioSolutions ($EBS) Is Paying a $40M Settlement to Investors — Here’s How to Get Your Share - TradingView
Emergent Biosolutions Inc (EBS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):